Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma - PubMed (original) (raw)
Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma
J Kuratsu et al. J Natl Cancer Inst. 1993.
Abstract
Background: Monocyte chemoattractant protein-1 (MCP-1) is a 76-amino acid protein that attracts monocytes. In vitro studies have reported high levels of MCP-1 messenger RNA expression, as well as the presence of MCP-1, in malignant glioma cells.
Purpose: Our purpose was to determine whether an MCP-1 assay could be used in a clinical setting 1) to differentiate malignant from benign gliomas and from nontumor disorders of the central nervous system and 2) to detect subarachnoid dissemination of glioma cells.
Methods: MCP-1 levels in cerebrospinal fluid (CSF) and cyst fluid were measured with a sandwich enzyme-linked immunosorbent assay (ELISA) that we had previously developed. We measured MCP-1 levels in CSF samples from 19 patients with malignant glioma (glioblastoma, 10; anaplastic astrocytoma, six; anaplastic oligodendroglioma, two; and ependymoblastoma, one), nine patients with benign glioma, and seven patients with nontumor disorders of the central nervous system. Cyst fluids from four patients with malignant glioma (anaplastic astrocytoma) were also tested. The correlation between MCP-1 concentration in the CSF and subarachnoid dissemination of malignant glioma cells was also studied.
Results: The MCP-1 concentration (mean +/- SE) in CSF samples from patients with malignant glioma (2.3 +/- 0.4 ng/mL) was significantly higher than that from patients with benign glioma (0.6 +/- 0.1 ng/mL) (P < .01) or from patients with no tumor (0.5 +/- 0.1 ng/mL) (P < .01). Furthermore, CSF samples from patients with subarachnoid dissemination of malignant glioma contained significantly higher amounts of MCP-1 than those from patients without dissemination (P < .05). Cyst fluids from four of the patients with malignant glioma contained high concentrations of MCP-1.
Conclusions: These results indicate that MCP-1 is produced by malignant glioma in vivo as well as in vitro and suggest that testing for MCP-1 in CSF may be useful in the clinic to differentiate malignant glioma from benign glioma and to detect subarachnoid dissemination of the tumor cells.
Implications: The MCP-1 ELISA in CSF may lead to more accurate diagnosis of malignant glioma and detection of subarachnoid dissemination of tumor cells, facilitating selection of patients with these conditions for appropriate therapy.
Similar articles
- Expression and localization of messenger RNA and protein for monocyte chemoattractant protein-1 in human malignant glioma.
Takeshima H, Kuratsu J, Takeya M, Yoshimura T, Ushio Y. Takeshima H, et al. J Neurosurg. 1994 Jun;80(6):1056-62. doi: 10.3171/jns.1994.80.6.1056. J Neurosurg. 1994. PMID: 8189261 - Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro.
Desbaillets I, Tada M, de Tribolet N, Diserens AC, Hamou MF, Van Meir EG. Desbaillets I, et al. Int J Cancer. 1994 Jul 15;58(2):240-7. doi: 10.1002/ijc.2910580216. Int J Cancer. 1994. PMID: 7517920 - Dissemination of supratentorial malignant gliomas via the cerebrospinal fluid in children.
Grabb PA, Albright AL, Pang D. Grabb PA, et al. Neurosurgery. 1992 Jan;30(1):64-71. doi: 10.1227/00006123-199201000-00012. Neurosurgery. 1992. PMID: 1738457 - Proteomic analysis of cerebrospinal fluid: toward the identification of biomarkers for gliomas.
Shen F, Zhang Y, Yao Y, Hua W, Zhang HS, Wu JS, Zhong P, Zhou LF. Shen F, et al. Neurosurg Rev. 2014 Jul;37(3):367-80; discussion 380. doi: 10.1007/s10143-014-0539-5. Epub 2014 May 1. Neurosurg Rev. 2014. PMID: 24781189 Review. - [Subarachnoid dissemination of the brain tumor cells (author's transl)].
Matsukado Y, Uemura S, Kuratsu J. Matsukado Y, et al. No Shinkei Geka. 1980 Dec;8(12):1113-23. No Shinkei Geka. 1980. PMID: 6454080 Review. Japanese. No abstract available.
Cited by
- A panel of four cytokines predicts the prognosis of patients with malignant gliomas.
Lin Y, Zhang G, Zhang J, Gao G, Li M, Chen Y, Wang J, Li G, Song SW, Qiu X, Wang Y, Jiang T. Lin Y, et al. J Neurooncol. 2013 Sep;114(2):199-208. doi: 10.1007/s11060-013-1171-x. Epub 2013 Jun 8. J Neurooncol. 2013. PMID: 23748572 - Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma.
Wang X, Guo G, Guan H, Yu Y, Lu J, Yu J. Wang X, et al. J Exp Clin Cancer Res. 2019 Feb 18;38(1):87. doi: 10.1186/s13046-019-1085-3. J Exp Clin Cancer Res. 2019. PMID: 30777100 Free PMC article. Review. - Immunotherapy of Primary Brain Tumors: Facts and Hopes.
Buerki RA, Chheda ZS, Okada H. Buerki RA, et al. Clin Cancer Res. 2018 Nov 1;24(21):5198-5205. doi: 10.1158/1078-0432.CCR-17-2769. Epub 2018 Jun 5. Clin Cancer Res. 2018. PMID: 29871908 Free PMC article. Review. - Immunotherapy for recurrent glioblastoma: practical insights and challenging prospects.
Wang X, Lu J, Guo G, Yu J. Wang X, et al. Cell Death Dis. 2021 Mar 19;12(4):299. doi: 10.1038/s41419-021-03568-0. Cell Death Dis. 2021. PMID: 33741903 Free PMC article. Review. - Crosstalk between β-Catenin and CCL2 Drives Migration of Monocytes towards Glioblastoma Cells.
Aretz P, Maciaczyk D, Yusuf S, Sorg RV, Hänggi D, Liu H, Liu H, Dakal TC, Sharma A, Bethanabatla R, Neumann S, Maciaczyk J. Aretz P, et al. Int J Mol Sci. 2022 Apr 20;23(9):4562. doi: 10.3390/ijms23094562. Int J Mol Sci. 2022. PMID: 35562953 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous